Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration — Stella

Home/Relapsed or Refractory Multiple Myeloma (RRMM)/Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

View on ClinicalTrials.gov

Recruiting

Back to Relapsed or Refractory Multiple Myeloma (RRMM) trials

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Shanghai Liquan Hospital, Shanghai

Key details

Phase

Early testing

Sponsor

Beijing GoBroad Hospital

Collaborators

Shanghai Liquan Hospital, Ruijin Hospital

Enrollment target

~18 participants

Started

May 2025

Primary completion

May 2027

Age range

18 Years – 75 Years

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.